InsidersTradesSigma
Follow the PHARMANUTRA PHARMANUTRA - PHN: IL CDA APPROVA IL PROGETTO DI BILANCIO DI ESERCIZIO E IL BILANCIO CONSOLIDATO AL 31 DICEMBRE 2025 stock price and the full management transaction log of the company, a listed issuer based in Italy. Shares trade on the IT market, under the oversight of Consob. Operating in the Health Care sector, PHARMANUTRA PHARMANUTRA - PHN: IL CDA APPROVA IL PROGETTO DI BILANCIO DI ESERCIZIO E IL BILANCIO CONSOLIDATO AL 31 DICEMBRE 2025 has recorded 0 insider filings. Market capitalisation: €799.5m. The full history is free.
n/a
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Fundamental score
Ranked 8,628 of 29,064 companies
61.7
score / 100
Value39
Quality85
FCF yld2.1%
Earn yld2.5%
EV/EBITDA23.9x
ROE30%
Gross mgn77%
Net mgn15%
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Declarations0 total
No declarations found
0 of 0 declarations
About PHARMANUTRA PHARMANUTRA - PHN: IL CDA APPROVA IL PROGETTO DI BILANCIO DI ESERCIZIO E IL BILANCIO CONSOLIDATO AL 31 DICEMBRE 2025
PHARMANUTRA is a company operating in the health and pharmaceutical sector, which has recently approved its draft financial statements and consolidated financial statements as of December 31, 2025.